← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Protego Biopharma, Inc.
San Diego, CA
$3,722,989
Total funding
3
Grants
Funding over time
peak $1.4M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,722,989 · 3
By mechanism
U44$2,768,762 · 1
R43$954,227 · 2
Investigators at Protego Biopharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)$1,368,143
U44 · FY2021 · NS
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)$700,619
U44 · FY2023 · NS
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)$700,000
U44 · FY2020 · NS
Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses$419,185
R43 · FY2019 · NS
Development of an early diagnostic and biomarker of treatment response for TTR amyloidoses (ATTR)$325,000
R43 · FY2018 · TR
Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses$210,042
R43 · FY2020 · NS